atorvastatin has been researched along with dasatinib in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
Butte, AJ; De Vusser, K; Fischbein, MP; Gong, Y; Khatri, P; Kimura, N; Morgan, AA; Naesens, M; Robbins, RC; Roedder, S; Sarwal, MM | 1 |
2 review(s) available for atorvastatin and dasatinib
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 other study(ies) available for atorvastatin and dasatinib
Article | Year |
---|---|
A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation.
Topics: Allografts; Animals; Atorvastatin; Biopsy; Cohort Studies; Dasatinib; Databases as Topic; Disease Models, Animal; Drug Approval; Electronic Health Records; Gene Expression Regulation; Gene Regulatory Networks; Graft Rejection; Graft Survival; Heart Transplantation; Heptanoic Acids; Humans; Kidney; Kidney Transplantation; Meta-Analysis as Topic; Mice; Mice, Inbred C57BL; Molecular Targeted Therapy; Organ Specificity; Pyrimidines; Pyrroles; Reproducibility of Results; Retrospective Studies; Thiazoles; Transplantation; United States; United States Food and Drug Administration | 2013 |